Abstract
Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19.
【초록키워드】 COVID-19, Treatment, Stratification, SARS-CoV-2, IP-10, interleukin-6, progression, Peripheral blood, T cell, management, Patient, disease, SARS-CoV-2-specific antibodies, dendritic cell, Phenotypes, traits, cohorts, upregulation, heterogeneous, selective, offer, Cell, independent, immune signature, identify, include, subsequent, changes in, Improved, greatly reduce, patients with COVID-19, phasic, potentially life-threatening, 【제목키워드】 COVID-19, association, poor prognosis, immune signature, include,